Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6e29526f284c0155fd79806c9dd5a1c7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-065 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2842 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-06 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6887 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P13-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-564 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00 |
filingDate |
2013-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6d0140a6b5b31b1bf78d9e85b8cb056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89daba5fc0153cb9e72a46ea4f8bed06 |
publicationDate |
2017-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
ES-2646598-T3 |
titleOfInvention |
Diagnosis and treatment of bowel and bladder motility disorders, and fibromyalgia |
abstract |
One method, comprising: providing a biological sample of a subject that requires the diagnosis of a gastrointestinal motility disorder, bladder motility disorder or fibromyalgia; detect in the biological sample, a presence or a level of an anti-vinculin antibody; and determine the presence or probable presence of irritable bowel syndrome (IBS) if the presence of the anti-vinculin antibody is detected, if the level of the anti-vinculin antibody is higher than an established control level, or if the level of the antibody anti-vinculin is significantly higher than an established control level, or determine an absence or probable absence of irritable bowel syndrome (IBS) if an absence of the anti-vinculin antibody is detected, if the level of the anti-vinculin antibody is equal or lower than the level of the established control, or if the level of the anti-vinculin antibody is not significantly higher than a level of the established control. |
priorityDate |
2012-09-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |